Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

AMD1

 

Progression Of Macular Atrophy In Patients With Neovascular Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy

AMD2

 

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials

AMD3

 

Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration

AMD4

 

To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration?

AMD5